Holen Sie sich die Stockscreener-App
1.86
3.33%
0.06
Schlusskurs vom Vortag:
$1.80
Offen:
$1.93
24-Stunden-Volumen:
114.36K
Relative Volume:
4.52
Marktkapitalisierung:
$10.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.4662
EPS:
-3.99
Netto-Cashflow:
$-12.27M
1W Leistung:
+14.81%
1M Leistung:
+21.01%
6M Leistung:
-42.77%
1J Leistung:
-66.73%
1-Tages-Spanne:
$1.86
$2.01
1-Wochen-Bereich:
$1.45
$2.01
52-Wochen-Spanne:
$1.412
$5.80
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Vergleichen Sie APRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.86 | 8.95M | 0 | -14.29M | -12.27M | -3.99 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
Wedbush Forecasts Lower Earnings for Aprea Therapeutics - Defense World
Petro-Victory Energy Corp. Announces Short Term Loan - Barchart.com
Strathcona Resources Ltd. Reports First Quarter 2025 Financial and Operating Results, Announces Quarterly Dividend and Investment in MEG Energy Corp. - Barchart.com
Aprea Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
NoticeGO-TO DEVELOPMENTS HOLDINGS INC., GO-TO SPADINA ADELAIDE SQUARE INC., FURTADO HOLDINGS INC., and OSCAR FURTADO, File No. 2022-8 - Barchart.com
RBC Global Asset Management Inc. Announces RBC ETF Cash Distributions For May 2025 - Barchart.com
Strathcona Resources Ltd. Announces Sale of Montney Business for $2.84 Billion and Acquisition of Hardisty Rail Terminal - Barchart.com
BIG ROCK BREWERY INC. ANNOUNCES RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS - Barchart.com
This Under-The-Radar Cancer Biotech Reports 21% Tumor Shrinkage: Analysts See 600%+ Upside - Barchart.com
GFL Environmental Inc. Announces Results From Annual General Meeting Of Shareholders - Barchart.com
Aprea (APRE) Reports Q1 Revenue Drop Amid Clinical Progress | AP - GuruFocus
APRE Reports Decrease in Cash Reserves by End of Q1 2025 | APRE Stock News - GuruFocus
Aprea Therapeutics Reports Promising Q1 2025 Results - TipRanks
Aprea Therapeutics reports Q1 EPS (66c) vs. (67c) last year - TipRanks
Aprea Therapeutics, Inc. SEC 10-Q Report - TradingView
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - The Manila Times
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewswire Inc.
Stocks In Play: Knight Therapeutics Inc - Barchart.com
NRx Pharmaceuticals (NASDAQ: NRXP) To Report Q1 2025 Results On May 15 - Barchart.com
Aprea Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Stocks In Play: Galiano Gold Inc. - Barchart.com
Stocks In Play: Illumin Holdings Inc. - Barchart.com
LifeSpeak Inc. Announces First Quarter 2025 Results - Barchart.com
Stocks In Play: Knight Therapeutics Inc. - Barchart.com
WILLOW BIOSCIENCES INC. ANNOUNCES $30.0 MILLION RECAPITALIZATION FINANCING AND PROPOSED APPOINTMENT OF NEW EXECUTIVE TEAM AND BOARD OF DIRECTORS TO FORM ATLAS ENERGY CORP. - Barchart.com
Adicet Bio Advances Two Breakthrough Therapies: Key Clinical Data Coming in 2025 for Lupus and Cancer Programs - Stock Titan
IGM FINANCIAL INC. ANNOUNCES APRIL 2025 ASSETS UNDER MANAGEMENT & ADVISEMENT AND NET FLOWS - Barchart.com
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MyChesCo
LPL Financial LLC Makes New $53,000 Investment in Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
Stocks In Play: Boyd Group Services Inc. - Barchart.com
Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies - MyChesCo
Halda Therapeutics Announces Appointment of Eyal Attar, MD, as Chief Medical Officer - Business Wire
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo
APRE stock touches 52-week low at $1.5 amid market challenges - Investing.com Australia
Adicet Bio Strengthens Board with Ex-Johnson & Johnson VP: Strategic Move for Cell Therapy Pioneer - Stock Titan
Adicet Bio Appoints Michael Grissinger to the Board of Directors - Business Wire
INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences - MyChesCo
Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion - MSN
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MSN
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
APRE stock touches 52-week low at $1.74 amid market challenges - Investing.com
Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock By Investing.com - Investing.com India
Aprea Therapeutics President/CEO Gilad Oren Acquires 5,500 Shares - TradingView
Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock - Investing.com
Breaking Down Early Signs and Symptoms of Head and Neck Cancer - Curetoday
Biotech Alert: Searches spiking for these stocks today - TipRanks
Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aprea Therapeutics Inc-Aktie (APRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Duey Marc | Director |
Oct 18 '24 |
Sale |
4.58 |
6,462 |
29,583 |
233,651 |
| Gilad Oren | President/CEO |
Oct 23 '24 |
Buy |
3.92 |
500 |
1,958 |
333,395 |
| Duey Marc | Director |
Oct 16 '24 |
Buy |
4.39 |
30,000 |
131,700 |
240,113 |
| Gilad Oren | President/CEO |
Oct 15 '24 |
Buy |
2.90 |
250 |
725 |
332,895 |
| Duey Marc | Director |
Oct 14 '24 |
Buy |
2.58 |
190 |
490 |
210,113 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 11 '24 |
Buy |
2.46 |
50 |
123 |
19,368 |
| Seizinger Bernd R. | Director |
Oct 11 '24 |
Buy |
2.68 |
10,000 |
26,800 |
44,730 |
| Gilad Oren | President/CEO |
Oct 14 '24 |
Buy |
2.59 |
1,000 |
2,590 |
332,645 |
| Gilad Oren | President/CEO |
Oct 10 '24 |
Buy |
2.54 |
150 |
381 |
331,645 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 10 '24 |
Buy |
2.61 |
450 |
1,174 |
19,318 |
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):